Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension, and advance additional clustering antibody drug candidates
DIAG723 is expected to enter the clinic in first half of 2026
WATERTOWN, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company developing disease-modifying clustering antibodies that correct dysregulated signaling in severe genetic diseases, today announced the closing of an oversubscribed $125 million Series B financing co-led by Sanofi Ventures and Janus Henderson Investors, with participation from both existing and new investors. New investors include Deep Track Capital, EcoR1 Capital, Logos Capital, Balyasny Asset Management L.P. and Woodline Partners LP. Existing investors include Atlas Venture, BVF Partners, Lightspeed Venture Partners, RA Capital Management, Frazier Life Sciences, Viking Global Investors, RV Invest, Velosity Capital, Biovision Ventures and Checkpoint Capital. Paulina Hill, Ph.D., Partner at Sanofi Ventures, will join Diagonal's Board of Directors in conjunction with the financing.
Proceeds will support advancement of DIAG723, a first-in-class, disease-modifying clustering antibody designed to correct the underlying cause of hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH), conditions that collectively impact hundreds of thousands of people around the world. Diagonal expects to initiate its first-in-human trial for DIAG723 in HHT patients during the first half of ...
